547 related articles for article (PubMed ID: 29142136)
1. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
2. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
3. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics.
Karris MY; Umlauf A; Vaida F; Richman D; Little S; Smith D
Medicine (Baltimore); 2016 Nov; 95(44):e5315. PubMed ID: 27858912
[TBL] [Abstract][Full Text] [Related]
5. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
6. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
[TBL] [Abstract][Full Text] [Related]
8. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
[TBL] [Abstract][Full Text] [Related]
10. Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.
Osborne BJ; Sheth PM; Yi TJ; Kovacs C; Benko E; Porte Cl; Huibner S; Le AQ; Danroth R; Baraki B; Mazzulli T; Brumme ZL; Kaul R
J Infect Dis; 2013 Apr; 207(8):1226-34. PubMed ID: 23329849
[TBL] [Abstract][Full Text] [Related]
11. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
Reuter S; Braken P; Jensen B; Sierra-Aragon S; Oette M; Balduin M; Kaiser R; Häussinger D
Eur J Med Res; 2010 Jun; 15(6):231-7. PubMed ID: 20696631
[TBL] [Abstract][Full Text] [Related]
12. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
[TBL] [Abstract][Full Text] [Related]
14. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A;
Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
Beliakova-Bethell N; Jain S; Woelk CH; Witt MD; Sun X; Lada SM; Spina CA; Goicoechea M; Rought SE; Haubrich R; Dubé MP
Antiviral Res; 2014 Jul; 107():42-9. PubMed ID: 24769244
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain.
Kelly KM; Beck SE; Metcalf Pate KA; Queen SE; Dorsey JL; Adams RJ; Avery LB; Hubbard W; Tarwater PM; Mankowski JL
AIDS; 2013 Nov; 27(18):F21-8. PubMed ID: 24051706
[TBL] [Abstract][Full Text] [Related]
19. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
20. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
